TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12421175
Drug: Mifepristone 600
Normalized name: Mifepristone 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 600 mg orally + Misoprostol 0.4 mg vaginally (Mf + Ms)
Study: 12421175
Drug: Misoprostol 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 0.4 mg vaginally (Ms)
Study: 9871426
Drug: Fexofenadine hydrochloride
Normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine hydrochloride (single doses of 10 to 800 mg)
Study: 9871426
Drug: Fexofenadine hydrochloride
Normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine hydrochloride (multiple doses of 20 to 690 mg twice daily for 28 1/2 days)
Study: 977791
Drug: Chlordesmethyldiazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordesmethyldiazepam (2 mg)
Study: 977791
Drug: Chlordesmethyldiazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordesmethyldiazepam (1 mg)
Study: 31220991
Drug: Four-step tapering
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-step tapering (DRESS strategy)
Study: 31220991
Drug: Five-step tapering
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Five-step tapering
Study: 31220991
Drug: Tapering without
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapering without withdrawal
Study: 31220991
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of a theoretical predictor for successful tapering
Study: 31220991
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of treatment
Study: 21932661
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT), once a day for 6 consecutive days
Study: 21932661
Drug: Control group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group, no treatment specified
Study: 18377145
Drug: Children's medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children's medication use
Study: 12683268
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (preferential indication for clozapine)
Study: 12683268
Drug: Long-acting depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting depot neuroleptic preparations
Study: 12683268
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics in acute and long-acting intramuscular forms
Study: 12683268
Drug: Adjunctive medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive medications
Study: 8826489
Drug: Topical indomethacin/diethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical indomethacin/diethyl ether mixture
Study: 8826489
Drug: Topical diclofenac/diethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac/diethyl ether mixture
Study: 1419008
Drug: Amantadine 1
Normalized name: amantadine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 1 g orally in divided doses over a period of 25 hours prior to surgery, along with diazepam 5 mg orally 1 hour prior to induction of anesthesia.
Study: 1419008
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg orally 1 hour prior to induction of anesthesia (Control group).
Study: 31793646
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements for pregnant and lactating women and children 6-59 months of age
Study: 28459136
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg grapiprant (oral administration)
Study: 28459136
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg grapiprant (i.v. administration)
Study: 24220326
Drug: MenACWY‐CRM with
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY‐CRM with routine vaccines
Study: 7890057
Drug: Cyclic sodium
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic sodium etidronate and low-dose norethindrone (2.5 mg daily) with GnRH agonist leuprolide acetate IM monthly for 48 weeks (Group I)
Study: 7890057
Drug: Low-dose norethindrone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose norethindrone (10 mg daily) with GnRH agonist leuprolide acetate IM monthly for 48 weeks (Group II)
Study: 31043177
Drug: Rifampicin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin treatment for up to 31 days
Study: 20383544
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant loading within 1 week after implant insertion
Study: 20383544
Drug: Conventional loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional loading of palatal implants after a healing period of 12 weeks
Study: 19448380
Drug: Carbohydrate-rich drink
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-rich drink (12.5 g carbohydrates/100 ml, pH 5.0) given shortly before surgery
Study: 11934726
Drug: Prolonged methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged methylprednisolone administration
Study: 9806049
Drug: Ganciclovir from
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir from engraftment without prior acyclovir treatment (Group 1)
Study: 9806049
Drug: Ganciclovir at
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir at engraftment with prior intravenous acyclovir (500 mg/m2 every 8 h) (Group 3)
Study: 347294
Drug: Human leukocyte
Normalized name: Human leukocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human leukocyte interferon (two highest dosage levels)
Study: 31424576
Drug: mFOLFOX6 chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 chemotherapy with SIRT (yttrium-90 resin microspheres)
Study: 31424576
Drug: mFOLFOX6 chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 chemotherapy without SIRT (control arm)
Study: 29336621
Drug: Beta-Alanine (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-Alanine (3.2 g/day)
Study: 26818850
Drug: Prophylactic amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic amiodarone (5 mg/kg IV loading dose, continuous infusion of 10-15 μg/kg/min for 3 days)
Study: 22174436
Drug: 1-g dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-g dose of doripenem administered intravenously over 4 hours
Study: 22174436
Drug: 2-g dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-g dose of doripenem administered intravenously over 4 hours
Study: 22174436
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg and 1 g doses of doripenem administered over 4 hours in adult healthy volunteers (HVs)
Study: 16412928
Drug: Gatifloxacin 0.3%
Normalized name: GATIFLOXACIN 0.3% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 0.3% instilled hourly for 10 hours
Study: 16412928
Drug: Moxifloxacin 0.5%
Normalized name: Moxifloxacin 0.5%, Bromfenac 0.075% Ophthalmic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 0.5% instilled hourly for 10 hours
Study: 12441586
Drug: Chicken Soup
Normalized name: Multimineral/Multivitamin Oral Tablet [CHICKEN SOUP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chicken Soup for the Soul at Work Employee Groups intervention, consisting of nine weekly meetings.
Study: 7570433
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol 5 mg and ipratropium bromide 500 micrograms (4 times a day)
Study: 7570433
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol 5 mg alone (4 times a day)
Study: 519476
Drug: Praziquantel split
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel split regimen (two doses of 20 mg/kg given four hours apart)
Study: 27853049
Drug: Monthly regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly regimen (MR): 1.5 g iv methylprednisolone monthly for 3 months
Study: 27853049
Drug: Weekly regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly regimen (WR): 0.5 g iv methylprednisolone weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks
Study: 23863351
Drug: Anodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal tDCS (1.5 mA, 15 min, daily for five days a week, for three weeks)
Study: 19743621
Drug: modified multidrug
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified multidrug therapy (mMDT) including rifampicin, clofazimine, and dapsone for 1 year
Study: 17082663
Drug: Thrice-weekly low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thrice-weekly low-dose rituximab (20 mg/m2)
Study: 17082663
Drug: Thrice-weekly low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thrice-weekly low-dose rituximab (60 mg/m2)
Study: 17082663
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose infusion of rituximab (375 mg/m2)
Study: 11402249
Drug: Carbohydrate supplementation
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplementation (CHO) 1.0 g á kg body mass(‐1)
Study: 9424000
Drug: Sucralfate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (3 g in 15 ml suspension, once daily enema during and for 2 weeks following radiotherapy)
Study: 9424000
Drug: Placebo (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (15 ml suspension, once daily enema during and for 2 weeks following radiotherapy)
Study: 3030392
Drug: Combined oestrogen-CPA
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oestrogen-CPA therapy
Study: 31982885
Drug: Levosimendan (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (treatment group)
Study: 16522992
Drug: Doxazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin GITS 4 mg/d
Study: 16522992
Drug: Doxazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin GITS 8 mg/d (if needed)
Study: 11217682
Drug: Combined vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vaccine against tetanus, diphtheria and polio (Td-IPV)
Study: 11217682
Drug: Separate Td
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate Td and IPV injections
Study: 9387055
Drug: Antihyperthyroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihyperthyroid therapy
Study: 8329293
Drug: Moclobemide treatment
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide treatment (200 mg twice daily)
Study: 3791629
Drug: Ketotifen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (2 mg every 12 hr for one week)
Study: 27460004
Drug: Mindfulness training
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness training (MYmind protocol) consisting of 8 weekly 1.5-hour sessions
Study: 27460004
Drug: Short-acting methylphenidate
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting methylphenidate administered individually
Study: 15920062
Drug: Fenofibrate 200
Normalized name: fenofibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 200 mg daily for 8 weeks
Study: 11459384
Drug: Nutritional therapy
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional therapy (NT)
Study: 11459384
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cognitive and nutritional therapy (CNT)
Study: 9220308
Drug: Urapidil (60-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (60-120 mg/d)
Study: 3600277
Drug: antithyroid drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: antithyroid drug methimazole + thyroxine
Study: 3600277
Drug: beta 1‐selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta 1‐selective adrenoceptor blocking agent metoprolol
Study: 20701025
Drug: Digoxin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (single oral dose)
Study: 20701025
Drug: Digoxin with
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin with simultaneous administration of methimazole (in 12 patients)
Study: 20701025
Drug: Methimazole treatment
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole treatment (in 12 patients who were re-assessed after becoming euthyroid)
Study: 18237823
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (PUFAs) 1 g b.i.d. for 3 months
Study: 18237823
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no change in pre-enrollment therapy)
Study: 12615677
Drug: Simvastatin, Atorvastatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin, Atorvastatin, Cerivastatin
Study: 27590465
Drug: Swedish massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swedish massage therapy
Study: 20486905
Drug: Everolimus (Evr)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (Evr) monotherapy after 10 days of cyclosporine (CsA)
Study: 20486905
Drug: Everolimus (Evr)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (Evr) monotherapy
Study: 17464918
Drug: Chlorhexidine mouthwash
Normalized name: chlorhexidine Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine mouthwash (0.2%) administered for 30 seconds before dental manipulation
Study: 7619663
Drug: Buspirone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (30 mg day‐1 for 4 days and 10 mg on day 5)
Study: 7619663
Drug: Ipsapirone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipsapirone (15 mg day‐1 for 4 days and 5 mg on day 5)
Study: 7619663
Drug: Clonidine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.15 mg intravenous administration)
Study: 19593248
Drug: 7-valent conjugate
Normalized name: PNEUMOCOCCAL 7-VALENT CONJUGATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent conjugate pneumococcal vaccine (PnCRM7)
Study: 19593248
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine randomized communities
Study: 16420549
Drug: Transdermal 17beta‐oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐oestradiol (tE2, n = 33)
Study: 16420549
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized 17beta‐oestradiol (oE2, n = 37)
Study: 16420549
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized 17beta‐oestradiol combined with gestodene (oE2 + G, n = 33)
Study: 15327582
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg kg(‐1) oral morphine sulphate
Study: 15327582
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg kg(‐1) oral oxycodone hydrochloride
Study: 15327582
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.25 mg kg(‐1) morphine sulphate with 0.25 mg kg(‐1) oxycodone hydrochloride
Study: 21911726
Drug: TAC (75/50/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC (75/50/500 mg/m² every 3 weeks)
Study: 21911726
Drug: AC (60/600
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC (60/600 mg/m² every 3 weeks) followed by docetaxel at 100 mg/m² every 3 weeks (AC>T)
Study: 18159093
Drug: Pravastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10 mg/daily, n=176)
Study: 18159093
Drug: Pravastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10 mg/daily)
Study: 1633064
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg) with intravenous frusemide (20 mg)
Study: 1633064
Drug: Frusemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (20 mg)
Study: 25791143
Drug: Telehealth service
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth service model (6 sessions over 22 weeks of combined pharmacotherapy and caregiver behavior training)
Study: 25791143
Drug: Control service
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control service delivery model (treatment with PCPs augmented with telepsychiatry consultation)
Study: 17302515
Drug: Fortified mineral
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified mineral water (1000 mL/day)
Study: 12588812
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human TSH and laser therapy
Study: 31967190
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (200ml inert solution)
Study: 28169879
Drug: Pirarubicin at
Normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirarubicin at 25 mg/m administered 11 times throughout the treatment
Study: 28169879
Drug: Standard-risk group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-risk group regimen with reinduction therapy
Study: 23320402
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine (TDB)
Study: 16500579
Drug: Warfarin (International
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (International Normalized Ratio 2.5-3)
Study: 8387607
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care plus cisplatin (75 mg/m2), cyclophosphamide (400 mg/m2), and mitomycin (10 mg/m2) given intravenously at 3-week intervals
Study: 28870155
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (200 mg capsules self-administered vaginally daily until 36 weeks gestation or delivery)
Study: 23633700
Drug: 20 percent
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 percent benzocaine gel
Study: 23633700
Drug: 10 percent
Normalized name: BENZOYL PEROXIDE 10 g in 100 mL TOPICAL LOTION [SMART RELEASE BPO 10 PERCENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 percent benzocaine gel
Study: 22010225
Drug: 250 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 µg/kg of vitamin D(3)
Study: 18971554
Drug: Irbesartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (100 mg tablet per day)
Study: 8989341
Drug: Inhaled furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled furosemide (1 mg/kg in 2 mL of saline)
Study: 8989341
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mL of saline)
Study: 8480077
Drug: Theophylline therapy
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline therapy after vitamin B6 supplementation
Study: 8480077
Drug: Theophylline therapy
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline therapy after placebo
Study: 3547879
Drug: Oral metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metoclopramide (20 mg)
Study: 31371616
Drug: DS‐Cav1 (stabilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS‐Cav1 (stabilized subunit vaccine candidate)
Study: 28760535
Drug: 18.8 mg
Normalized name: pemoline 18.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18.8 mg dose of AMP XR-ODT with 4% ethanol
Study: 28760535
Drug: 18.8 mg
Normalized name: pemoline 18.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18.8 mg dose of AMP XR-ODT with 20% ethanol
Study: 28760535
Drug: 18.8 mg
Normalized name: pemoline 18.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18.8 mg dose of AMP XR-ODT with 40% ethanol
Study: 28760535
Drug: 18.8 mg
Normalized name: pemoline 18.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18.8 mg dose of AMP XR-ODT with deionized water
Study: 26185766
Drug: Intramuscularly administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscularly administered drotaverine hydrochloride (40 mg)
Study: 21387350
Drug: Single-dose administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose administration of 0.5 mg metolazone
Study: 21387350
Drug: Single-dose administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose administration of 1 mg metolazone
Study: 21387350
Drug: Single-dose administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose administration of 2 mg metolazone
Study: 21387350
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 1 mg metolazone
Study: 12002908
Drug: roxithromycin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin (150 mg, twice daily)
Study: 9054280
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (11 mg for 1 week and then ≤ 22 mg for 3 weeks)
Study: 7697691
Drug: Benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 10 mg plus hydrochlorothiazide 12.5 mg once daily
Study: 7697691
Drug: Benazepril alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril alone (10 mg once daily)